|
Toxicity
|
Total No. of Patients
|
0.25 mL Group
|
1 mL Group
|
|---|
| |
0.25 mL
|
1 mL
|
Grade 1
|
Grade 2
|
Grade 1
|
Grade 2
|
Grade 3
|
|---|
|
Injection site induration
|
11
|
9
|
6
|
5
|
3
|
5
|
1
|
|
Injection site erythema
|
8
|
10
|
6
|
2
|
5
|
4
|
1
|
|
Injection site pain
|
3
|
8
|
1
|
2
|
3
|
5
| |
|
Injection site pruritis
|
3
|
2
|
3
| |
1
|
1
| |
|
Injection site warmth
|
2
|
2
|
1
|
1
|
1
|
1
| |
|
Injection site hematoma
|
2
| |
2
| | | | |
|
Injection site edema
|
1
|
4
|
1
| |
2
|
2
| |
|
Injection site discoloration
|
1
|
2
| |
1
|
2
| | |
|
Injection site rash
|
1
|
1
|
1
| | |
1
| |
|
Injection site urticaria
|
1
|
1
|
1
| | |
1
| |
|
Injection site dry skin
|
1
|
1
|
1
| |
1
| | |
|
Injection site ulceration
| |
3
| | |
1
| |
2*
|
|
Pain
|
3
|
1
|
2
|
1
| |
1
| |
|
Fatigue
|
2
| |
1
|
1
| | | |
|
Fever
|
1
|
2
| |
1
|
1
|
1
| |
|
Arthralgia
|
1
|
1
|
1
| |
1
| | |
|
Myalgia
|
1
|
1
|
1
| |
1
| | |
|
Anaemia
|
1
|
1
| |
1
| |
1
| |
- *Appeared three or more weeks after of third injection and completely resolved.
